Visterra Inc, a clinical-stage biotechnology company, recently published data that shows the effectiveness of its VIS410 in protecting people from both seasonal and potentially pandemic influenza strains.
Visterra’s novel monoclonal antibody, VIS410, targets a unique, conserved epitope on influenza A, and is being developed as a single administration for the treatment of seasonal and pandemic influenza, according to Zach Shriver, PhD, vice president of research at Visterra.
The company recently initiated a placebo-controlled Phase 2 challenge trial of VIS410 in healthy subjects administered an influenza virus in advance of receiving either VIS410 or placebo. Data from this trial will be available later this year.
Visterra Medication Proves Effective Against Influenza Strains
